SNDX · Syndax Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Michael A. Metzger President and COO | ▼ Sell | Open Market | 484,843 Shares held | 7/8/2026 | View profile |
| Dennis Podlesak | ▲ Buy | Grant | 239,763 Shares held | 2/4/2026 | View profile |
| Keith A. Goldan Chief Financial Officer | ▼ Sell | Open Market | 139,252 Shares held | 6/1/2026 | View profile |
| Keith Katkin Director | ▲ Buy | Grant | 124,000 Shares held | 2/4/2026 | View profile |
| Jennifer Jarrett Director, President and CEO | ▲ Buy | Grant | 114,000 Shares held | 2/4/2026 | View profile |
| Pierre Legault Director | ▲ Buy | Grant | 114,000 Shares held | 2/4/2026 | View profile |
| Martin H. Huber Jr. | ▲ Buy | Grant | 103,000 Shares held | 2/4/2026 | View profile |
| William Meury Chief Executive Officer | ▲ Buy | Grant | 90,000 Shares held | 2/5/2025 | View profile |
| Neil Gallagher President, Head of R&D | ▼ Sell | Open Market | 85,095 Shares held | 2/10/2025 | View profile |
| Nicholas A.J. Botwood Head of R&D, CMO | ▼ Sell | Open Market | 60,885 Shares held | 6/12/2026 | View profile |
| Aleksandra Rizo | ▲ Buy | Grant | 49,000 Shares held | 2/4/2026 | View profile |
| Morrison Briggs Director | ▲ Buy | Grant | 34,836 Shares held | 2/7/2024 | View profile |
| Egros Fabrice | ▲ Buy | Grant | 32,000 Shares held | 2/2/2022 | View profile |
| Meyers Michael L. SVP, Chief Medical Officer | ▼ Sell | Other | 23,280 Shares held | 1/31/2022 | View profile |
| Ordentlich Peter Chief Scientific Officer | ▼ Sell | Open Market | 0 Shares held | 2/15/2023 | View profile |
| Nolte Alexander Chief Accounting Officer | ▼ Sell | Open Market | 0 Shares held | 2/1/2022 | View profile |
Transaction History
| Michael A. Metzger | ▲ Buy | Option Exercise | 32,375 | $207K | 7/8/2026 |
| Michael A. Metzger | ▼ Sell | Open Market | 32,375 | $785K | 7/8/2026 |
| Nicholas A.J. Botwood | ▲ Buy | Option Exercise | 31,235 | $432K | 6/12/2026 |
| Nicholas A.J. Botwood | ▼ Sell | Open Market | 31,235 | $567K | 6/12/2026 |
| Nicholas A.J. Botwood | ▲ Buy | Option Exercise | 22,515 | $311K | 6/11/2026 |
| Nicholas A.J. Botwood | ▼ Sell | Open Market | 34,280 | $617K | 6/11/2026 |
| Keith A. Goldan | ▼ Sell | Open Market | 1,177 | $22K | 6/1/2026 |
| Michael A. Metzger | ▼ Sell | Open Market | 6,847 | $130K | 6/1/2026 |
| Michael A. Metzger | ▼ Sell | Open Market | 17,159 | $361K | 2/9/2026 |
| Keith A. Goldan | ▼ Sell | Open Market | 3,410 | $72K | 2/9/2026 |
| Keith A. Goldan | ▼ Sell | Open Market | 2,082 | $43K | 2/6/2026 |
| Michael A. Metzger | ▼ Sell | Open Market | 7,412 | $153K | 2/6/2026 |
| Pierre Legault | ▲ Buy | Grant | 24,000 | $0 | 2/4/2026 |
| Jennifer Jarrett | ▲ Buy | Grant | 24,000 | $0 | 2/4/2026 |
| Martin H. Huber Jr. | ▲ Buy | Grant | 24,000 | $0 | 2/4/2026 |
| Nicholas A.J. Botwood | ▲ Buy | Grant | 24,000 | $0 | 2/4/2026 |
| Nicholas A.J. Botwood | ▲ Buy | Grant | 36,000 | $0 | 2/4/2026 |
| Dennis Podlesak | ▲ Buy | Grant | 48,000 | $0 | 2/4/2026 |
| Aleksandra Rizo | ▲ Buy | Grant | 24,000 | $0 | 2/4/2026 |
| Keith Katkin | ▲ Buy | Grant | 24,000 | $0 | 2/4/2026 |
| Michael A. Metzger | ▲ Buy | Grant | 73,000 | $0 | 2/4/2026 |
| Michael A. Metzger | ▲ Buy | Grant | 144,600 | $0 | 2/4/2026 |
| Keith A. Goldan | ▲ Buy | Grant | 21,500 | $0 | 2/4/2026 |
| Keith A. Goldan | ▲ Buy | Grant | 30,750 | $0 | 2/4/2026 |
| Keith A. Goldan | ▼ Sell | Other | 1,219 | $10K | 1/30/2026 |
| Keith A. Goldan | ▼ Sell | Gift | 1,224 | $0 | 12/1/2025 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 157,307 | $1.7M | 9/8/2025 |
| Michael A. Metzger | ▼ Sell | Open Market | 157,307 | $2.6M | 9/8/2025 |
| Dennis Podlesak | ▲ Buy | Option Exercise | 19,200 | $138K | 8/18/2025 |
| Dennis Podlesak | ▼ Sell | Open Market | 19,200 | $304K | 8/18/2025 |
| Dennis Podlesak | ▲ Buy | Option Exercise | 19,200 | $138K | 8/15/2025 |
| Dennis Podlesak | ▼ Sell | Open Market | 19,200 | $298K | 8/15/2025 |
| Dennis Podlesak | ▲ Buy | Option Exercise | 19,200 | $138K | 8/14/2025 |
| Dennis Podlesak | ▼ Sell | Open Market | 19,200 | $273K | 8/14/2025 |
| Keith A. Goldan | ▼ Sell | Other | 1,226 | $10K | 7/31/2025 |
| Michael A. Metzger | ▼ Sell | Open Market | 7,534 | $70K | 7/16/2025 |
| Keith A. Goldan | ▼ Sell | Open Market | 1,296 | $12K | 7/16/2025 |
| Keith A. Goldan | ▲ Buy | Open Market | 3,000 | — | 5/19/2025 |
| Keith Katkin | ▲ Buy | Open Market | 10,000 | $91K | 5/19/2025 |
| Martin H. Huber Jr. | ▲ Buy | Open Market | 5,000 | $45K | 5/19/2025 |
| Nicholas A.J. Botwood | ▲ Buy | Open Market | 11,765 | $106K | 5/16/2025 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 6,074 | $44K | 3/14/2025 |
| Michael A. Metzger | ▼ Sell | Open Market | 7,814 | $118K | 3/4/2025 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 7,814 | $56K | 3/4/2025 |
| Keith A. Goldan | ▼ Sell | Open Market | 3,777 | $59K | 2/10/2025 |
| Michael A. Metzger | ▼ Sell | Open Market | 13,288 | $206K | 2/10/2025 |
| Neil Gallagher | ▼ Sell | Open Market | 4,618 | $72K | 2/10/2025 |
| Neil Gallagher | ▲ Buy | Grant | 18,500 | $0 | 2/5/2025 |
| Neil Gallagher | ▲ Buy | Grant | 23,400 | $0 | 2/5/2025 |
| Keith A. Goldan | ▲ Buy | Grant | 18,500 | $0 | 2/5/2025 |
| Keith A. Goldan | ▲ Buy | Grant | 23,400 | $0 | 2/5/2025 |
| Michael A. Metzger | ▲ Buy | Grant | 60,500 | $0 | 2/5/2025 |
| Michael A. Metzger | ▲ Buy | Grant | 89,000 | $0 | 2/5/2025 |
| Dennis Podlesak | ▲ Buy | Grant | 50,000 | $0 | 2/5/2025 |
| Aleksandra Rizo | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 |
| William Meury | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 |
| Keith Katkin | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 |
| Jennifer Jarrett | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 |
| Martin H. Huber Jr. | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 |
| Pierre Legault | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 |
| Keith A. Goldan | ▲ Buy | Open Market | 1,250 | $25K | 6/14/2024 |
| Michael A. Metzger | ▲ Buy | Grant | 107,250 | $0 | 2/7/2024 |
| Michael A. Metzger | ▲ Buy | Grant | 39,000 | $0 | 2/7/2024 |
| Keith A. Goldan | ▲ Buy | Grant | 35,000 | $0 | 2/7/2024 |
| Keith A. Goldan | ▲ Buy | Grant | 11,700 | $0 | 2/7/2024 |
| Neil Gallagher | ▲ Buy | Grant | 34,688 | $0 | 2/7/2024 |
| Neil Gallagher | ▲ Buy | Grant | 13,125 | $0 | 2/7/2024 |
| Martin H. Huber Jr. | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 |
| Jennifer Jarrett | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 |
| Keith Katkin | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 |
| William Meury | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 |
| Morrison Briggs | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 |
| Dennis Podlesak | ▲ Buy | Grant | 34,000 | $0 | 2/7/2024 |
| Pierre Legault | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 |
| Keith A. Goldan | ▼ Sell | Other | 1,183 | $21K | 1/31/2024 |
| Morrison Briggs | ▲ Buy | Option Exercise | 52,855 | $464K | 8/9/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 52,855 | $965K | 8/9/2023 |
| William Meury | ▲ Buy | Option Exercise | 35,000 | $249K | 8/2/2023 |
| William Meury | ▼ Sell | Open Market | 35,000 | $716K | 8/2/2023 |
| William Meury | ▲ Buy | Option Exercise | 24,000 | $189K | 8/2/2023 |
| William Meury | ▼ Sell | Open Market | 24,000 | $491K | 8/2/2023 |
| William Meury | ▲ Buy | Option Exercise | 24,000 | $227K | 8/2/2023 |
| William Meury | ▼ Sell | Open Market | 24,000 | $491K | 8/2/2023 |
| Keith A. Goldan | ▼ Sell | Other | 862 | $16K | 7/31/2023 |
| Morrison Briggs | ▲ Buy | Option Exercise | 52,855 | $464K | 7/10/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 52,855 | $1.1M | 7/10/2023 |
| Keith A. Goldan | ▼ Sell | Open Market | 577 | $13K | 6/13/2023 |
| Morrison Briggs | ▲ Buy | Option Exercise | 24,582 | $157K | 6/9/2023 |
| Morrison Briggs | ▲ Buy | Option Exercise | 28,273 | $248K | 6/9/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 24,582 | $521K | 6/9/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 28,273 | $599K | 6/9/2023 |
| Morrison Briggs | ▲ Buy | Option Exercise | 52,855 | $337K | 5/9/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 52,855 | $1.1M | 5/9/2023 |
| Morrison Briggs | ▲ Buy | Option Exercise | 52,855 | $337K | 4/10/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 52,855 | $1.0M | 4/10/2023 |
| Morrison Briggs | ▲ Buy | Option Exercise | 52,854 | $337K | 3/13/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 52,854 | $1.2M | 3/13/2023 |
| Ordentlich Peter | ▲ Buy | Option Exercise | 7,572 | $48K | 2/15/2023 |
| Ordentlich Peter | ▼ Sell | Open Market | 7,572 | $196K | 2/15/2023 |
| Ordentlich Peter | ▲ Buy | Option Exercise | 17,428 | $125K | 2/15/2023 |
| Ordentlich Peter | ▼ Sell | Open Market | 17,428 | $450K | 2/15/2023 |
| Morrison Briggs | ▼ Sell | Open Market | 52,854 | $1.4M | 2/6/2023 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 5,959 | $38K | 2/6/2023 |
| Michael A. Metzger | ▼ Sell | Open Market | 5,959 | $165K | 2/6/2023 |
| Morrison Briggs | ▲ Buy | Option Exercise | 52,854 | $337K | 2/6/2023 |
| Dennis Podlesak | ▲ Buy | Grant | 32,000 | $0 | 2/2/2023 |
| Martin H. Huber Jr. | ▲ Buy | Grant | 16,000 | $0 | 2/2/2023 |
| William Meury | ▲ Buy | Grant | 16,000 | $0 | 2/2/2023 |
| Pierre Legault | ▲ Buy | Grant | 16,000 | $0 | 2/2/2023 |
| Keith Katkin | ▲ Buy | Grant | 16,000 | $0 | 2/2/2023 |
| Jennifer Jarrett | ▲ Buy | Grant | 16,000 | $0 | 2/2/2023 |
| Ordentlich Peter | ▼ Sell | Open Market | 69 | $2K | 2/1/2023 |
| Ordentlich Peter | ▼ Sell | Other | 69 | $1K | 1/31/2023 |
| Pierre Legault | ▲ Buy | Option Exercise | 10,000 | $136K | 1/13/2023 |
| Pierre Legault | ▼ Sell | Open Market | 10,000 | $270K | 1/13/2023 |
| Pierre Legault | ▲ Buy | Option Exercise | 5,000 | $68K | 1/13/2023 |
| Pierre Legault | ▼ Sell | Open Market | 5,000 | $135K | 1/13/2023 |
| Pierre Legault | ▲ Buy | Option Exercise | 24,000 | $227K | 1/12/2023 |
| Pierre Legault | ▼ Sell | Open Market | 24,000 | $642K | 1/12/2023 |
| Ordentlich Peter | ▼ Sell | Open Market | 17,200 | $431K | 12/2/2022 |
| Ordentlich Peter | ▲ Buy | Option Exercise | 17,200 | $110K | 12/2/2022 |
| Ordentlich Peter | ▲ Buy | Option Exercise | 3,772 | $24K | 12/1/2022 |
| Ordentlich Peter | ▼ Sell | Open Market | 3,772 | $94K | 12/1/2022 |
| Ordentlich Peter | ▲ Buy | Option Exercise | 4,028 | $26K | 12/1/2022 |
| Ordentlich Peter | ▼ Sell | Open Market | 4,028 | $101K | 12/1/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 20,782 | $164K | 10/6/2022 |
| Keith Katkin | ▼ Sell | Open Market | 20,782 | $538K | 10/6/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 9,117 | $81K | 10/6/2022 |
| Keith Katkin | ▼ Sell | Open Market | 9,117 | $236K | 10/6/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 16,231 | $142K | 10/6/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 16,231 | $411K | 10/6/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 1,280 | $11K | 10/4/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 1,280 | $32K | 10/4/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 137 | $1K | 10/4/2022 |
| Keith Katkin | ▼ Sell | Open Market | 137 | $3K | 10/4/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 223 | $2K | 10/4/2022 |
| Keith Katkin | ▼ Sell | Open Market | 223 | $6K | 10/4/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 2,883 | $25K | 10/3/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 2,883 | $72K | 10/3/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 167 | $1K | 10/3/2022 |
| Keith Katkin | ▼ Sell | Open Market | 167 | $4K | 10/3/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 13 | $116 | 10/3/2022 |
| Keith Katkin | ▼ Sell | Open Market | 13 | $325 | 10/3/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 29,606 | $260K | 9/30/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 29,606 | $741K | 9/30/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 2,914 | $23K | 9/30/2022 |
| Keith Katkin | ▼ Sell | Open Market | 2,914 | $73K | 9/30/2022 |
| Keith Katkin | ▲ Buy | Option Exercise | 647 | $6K | 9/30/2022 |
| Keith Katkin | ▼ Sell | Open Market | 647 | $16K | 9/30/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 59,649 | $650K | 9/20/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 59,649 | $1.4M | 9/20/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 114,339 | $1.2M | 9/19/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 114,339 | $2.6M | 9/19/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 53,034 | $578K | 9/16/2022 |
| Dennis Podlesak | ▲ Buy | Option Exercise | 5,419 | $34K | 9/16/2022 |
| Dennis Podlesak | ▲ Buy | Option Exercise | 6,556 | $42K | 9/16/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 71,966 | $518K | 9/16/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 53,034 | $1.2M | 9/16/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 71,966 | $1.7M | 9/16/2022 |
| Dennis Podlesak | ▼ Sell | Open Market | 6,556 | $154K | 9/16/2022 |
| Dennis Podlesak | ▼ Sell | Open Market | 5,419 | $127K | 9/16/2022 |
| Dennis Podlesak | ▲ Buy | Option Exercise | 66,840 | $422K | 9/15/2022 |
| Dennis Podlesak | ▼ Sell | Open Market | 66,840 | $1.6M | 9/15/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 66,775 | $481K | 9/15/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 66,775 | $1.6M | 9/15/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 87,645 | $631K | 9/14/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 87,645 | $2.1M | 9/14/2022 |
| Ordentlich Peter | ▲ Buy | Option Exercise | 22,846 | $144K | 8/24/2022 |
| Ordentlich Peter | ▲ Buy | Option Exercise | 2,154 | $14K | 8/24/2022 |
| Ordentlich Peter | ▼ Sell | Open Market | 22,846 | $572K | 8/24/2022 |
| Ordentlich Peter | ▼ Sell | Open Market | 2,154 | $54K | 8/24/2022 |
| Pierre Legault | ▲ Buy | Option Exercise | 14,000 | $125K | 8/5/2022 |
| Pierre Legault | ▼ Sell | Open Market | 10,000 | $230K | 8/5/2022 |
| Pierre Legault | ▲ Buy | Option Exercise | 10,000 | $96K | 8/5/2022 |
| Pierre Legault | ▼ Sell | Open Market | 14,000 | $322K | 8/5/2022 |
| Ordentlich Peter | ▼ Sell | Other | 265 | $4K | 7/29/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 19,764 | $126K | 7/25/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 19,764 | $416K | 7/25/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 11,838 | $76K | 7/25/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 11,838 | $249K | 7/25/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 100 | $638 | 7/7/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 100 | $2K | 7/7/2022 |
| Michael A. Metzger | ▲ Buy | Option Exercise | 15,009 | $96K | 7/6/2022 |
| Michael A. Metzger | ▼ Sell | Open Market | 15,009 | $316K | 7/6/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 62,292 | $449K | 7/1/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 62,292 | $1.2M | 7/1/2022 |
| Keith A. Goldan | ▲ Buy | Grant | 3,205 | $0 | 6/13/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 3,128 | $34K | 4/4/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 3,128 | $57K | 4/4/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 6,000 | $105K | 4/1/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 24,500 | $427K | 4/1/2022 |
| Morrison Briggs | ▲ Buy | Option Exercise | 70,545 | $769K | 4/1/2022 |
| Morrison Briggs | ▼ Sell | Open Market | 70,545 | $1.2M | 4/1/2022 |
| Pierre Legault | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 |
| Egros Fabrice | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 |
| Jennifer Jarrett | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 |
| Keith Katkin | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 |
| Dennis Podlesak | ▲ Buy | Grant | 32,000 | $0 | 2/2/2022 |
| William Meury | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 |
| Martin H. Huber Jr. | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
SNDX Drops After Axatilimab IPF Trial Misses Endpoint
Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.
SNDX Drops After Axatilimab IPF Trial Misses Endpoint. Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.